News
CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...
The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...
Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...
Zacks Investment Research on MSN2d
GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo
Shares of Gilead Sciences, Inc. (GILD) tumbled 2.2% on Aug. 21, after pharmacy benefit manager CVS Health (CVS) decided not ...
CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...
Ian L. Haddock, founder of the Normal Anomaly Initiative, participated in the trials for lenacapavir, an FDA-approved drug ...
The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to HIV-prevention infrastructure in the U.S.
17don MSN
A proposed California bill aims to protect coverage for HIV prevention despite federal threats
When it comes to HIV prevention, the U.S. Supreme Court appeared to back up the task force with its July 11 ruling in Kennedy ...
FDA approves powerful HIV drug that nearly eliminated spread in clinical trials The twice-yearly injectable drug’s potential could be compromised by the Trump administration’s dramatic cuts to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback